Crescent Biopharma Inc Stock Price, News & Analysis

Crescent Biopharma (NASDAQ: CBIO) will present preclinical data for CR-001, a tetravalent PD-1 x VEGF bispecific antibody, at the Society for Immunotherapy of Cancer 40th Annual Meeting on November 7-9, 2025.

Key points: CR-001 showed cooperative pharmacology in vitro with increased PD-1 binding in the presence of VEGF, augmented PD-1/PD-L1 blockade, enhanced T-cell activation, potent anti-tumor activity in a xenograft model, and good tolerability plus robust PD-1 receptor occupancy in non-human primates. Crescent says an IND submission is on track for Q4 2025 to support a global Phase 1 trial planned to begin in Q1 2026. The poster (Abstract 1185) will be available on SITC and on Crescent’s website beginning 9:00 a.m. ET on the presentation day.

Crescent Biopharma (Nasdaq: CBIO), a biotechnology company focused on cancer therapies, has announced its participation in two major healthcare investor conferences in September 2025.

The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4, 2025, at 1:00 p.m. ET, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35 p.m. ET. Both events will take place in New York.

Webcasts will be available on the company's investor relations website, with replays accessible for 90 days.

Crescent Biopharma (NASDAQ:CBIO) reported Q2 2025 financial results and significant corporate developments. The company completed a merger with GlycoMimetics and secured a $200 million private financing. Under new leadership, including CEO Joshua Brumm, Crescent is advancing its cancer therapeutics pipeline.

The company's lead program, CR-001, a PD-1 x VEGF bispecific antibody, is progressing toward IND submission in Q4 2025, with proof-of-concept data expected in H2 2026. Two additional ADC programs, CR-002 and CR-003, are in development. Financial results show a cash position of $152.6 million, expected to fund operations through 2027, with a quarterly net loss of $21.8 million.

Crescent Biopharma (NASDAQ:CBIO) has appointed Jan Pinkas, Ph.D. as Chief Scientific Officer. Dr. Pinkas brings over 20 years of experience in oncology drug development, with expertise in antibody-drug conjugates (ADCs) and translational research.

The appointment comes at a crucial time as Crescent prepares to advance two key programs: CR-001, a PD-1 x VEGF bispecific antibody expected to begin Phase 1 trials in early 2026, and CR-002, a novel ADC with planned IND submission in mid-2026. Dr. Pinkas previously served as CSO at Pyxis Oncology and held senior positions at Magenta Therapeutics and ImmunoGen, where he contributed to the development of ELAHERE® for ovarian cancer and SARCLISA® for multiple myeloma.

Crescent Biopharma has completed its merger with GlycoMimetics and closed a $200 million private placement led by prominent healthcare investors. The combined company will trade on Nasdaq as CBIO starting June 16, 2025. Following a 1-for-100 reverse stock split, each Crescent share converted to 0.1445 shares of the combined company, resulting in approximately 19.5 million shares outstanding. The financing, along with existing cash, will fund operations through 2027. Crescent's lead program, CR-001, a PD-1 x VEGF bispecific antibody, is scheduled for IND submission in Q4 2025, with clinical data expected in H2 2026. The company is also developing two novel ADCs (CR-002 and CR-003) for use as single agents and in combination with CR-001, with CR-002's IND submission planned for mid-2026.

Catalyst Biosciences (NASDAQ: CBIO) announced key updates regarding asset transactions with GNI Group and GC Biopharma. The GNI Transactions involve acquiring the F351 Assets, linked to GNI's hydronidone compound, alongside its controlling interest in Beijing Continent Pharmaceutical, which reported $102 million in revenue for 2022. Meanwhile, Catalyst sold its rare bleeding disorders programs to GC Biopharma for $6 million, enhancing shareholder returns. The proceeds from this transaction will benefit stockholders of record as of January 5, 2023. Catalyst focuses on developing F351 for treating fibrotic diseases.

GC Biopharma has entered into an acquisition agreement with Catalyst Biosciences (CBIO) to obtain three programs focused on orphan hematology disorders. This includes the Phase 3-ready 'Marzeptacog alfa (MarzAA)', which has shown efficacy for rare bleeding disorders and offers the convenience of subcutaneous administration. GC Biopharma aims to leverage this acquisition to develop and launch a first-in-class drug, enhancing its position in global markets, particularly in the US. The move aligns with the company's commitment to improving therapeutic options for hemophilia and other rare disorders.